
Gennex Laboratories (GENNEX) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
341.8M
Gross Profit
119.8M
35.05%
Operating Income
45.7M
13.37%
Net Income
50.2M
14.68%
EPS (Diluted)
₹0.21
Balance Sheet Metrics
Total Assets
2.6B
Total Liabilities
614.5M
Shareholders Equity
1.9B
Debt to Equity
0.32
Cash Flow Metrics
Revenue & Profitability Trend
Gennex Laboratories Income Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Revenue | 1.4B | 791.0M | 649.6M | 611.8M | 596.3M |
Cost of Goods Sold | 982.2M | 500.5M | 408.6M | 386.7M | 367.0M |
Gross Profit | 393.3M | 290.5M | 241.0M | 225.0M | 229.3M |
Gross Margin % | 28.6% | 36.7% | 37.1% | 36.8% | 38.5% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | 33.5M | 21.5M | 30.4M | 25.2M | 27.3M |
Other Operating Expenses | 109.7M | 95.9M | 89.5M | 68.0M | 62.0M |
Total Operating Expenses | 143.1M | 117.4M | 119.9M | 93.2M | 89.4M |
Operating Income | 147.2M | 146.6M | 37.7M | 50.8M | 57.0M |
Operating Margin % | 10.7% | 18.5% | 5.8% | 8.3% | 9.6% |
Non-Operating Items | |||||
Interest Income | 95.7M | 37.9M | 26.6M | 9.0M | 538.2K |
Interest Expense | 36.1M | 30.8M | 13.5M | 8.8M | 7.4M |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 215.5M | 164.9M | 63.7M | 50.9M | 50.6M |
Income Tax | 32.7M | 33.2M | 14.5M | 11.7M | 10.2M |
Effective Tax Rate % | 15.2% | 20.1% | 22.8% | 23.0% | 20.2% |
Net Income | 181.2M | 131.8M | 49.2M | 39.2M | 40.4M |
Net Margin % | 13.2% | 16.7% | 7.6% | 6.4% | 6.8% |
Key Metrics | |||||
EBITDA | 271.7M | 213.6M | 83.6M | 72.5M | 70.6M |
EPS (Basic) | ₹0.80 | ₹0.67 | ₹0.32 | ₹0.31 | ₹0.30 |
EPS (Diluted) | ₹0.78 | ₹0.61 | ₹0.32 | ₹0.31 | ₹0.30 |
Basic Shares Outstanding | 227447674 | 186817062 | 146070205 | 126503000 | 132599530 |
Diluted Shares Outstanding | 227447674 | 186817062 | 146070205 | 126503000 | 132599530 |
Income Statement Trend
Gennex Laboratories Balance Sheet From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 545.9M | 602.3M | 142.1M | 74.9M | 1.9M |
Short-term Investments | 550.2M | 1.2B | 145.0M | 269.0M | 223.5M |
Accounts Receivable | 141.6M | 178.1M | 94.2M | 113.1M | 89.5M |
Inventory | 359.4M | 251.7M | 156.9M | 77.4M | 50.2M |
Other Current Assets | 8.4M | 8.4M | 6.7M | -1 | 11.7M |
Total Current Assets | 1.8B | 1.6B | 486.8M | 471.8M | 376.7M |
Non-Current Assets | |||||
Property, Plant & Equipment | 88.7M | 88.7M | 88.7M | 0 | 0 |
Goodwill | 29.4M | 29.4M | 61.1M | 0 | - |
Intangible Assets | 29.4M | 29.4M | - | - | - |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 88.0M | 88.7M | 88.7M | 1 | 2.8M |
Total Non-Current Assets | 749.1M | 681.7M | 836.3M | 208.4M | 212.3M |
Total Assets | 2.6B | 2.3B | 1.3B | 680.3M | 589.0M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 131.6M | 151.8M | 70.8M | 77.4M | 59.4M |
Short-term Debt | 102.2M | 57.2M | 10.5M | 101.2M | 73.6M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | - | - | - | - | 29.2M |
Total Current Liabilities | 445.6M | 403.0M | 295.1M | 242.1M | 190.2M |
Non-Current Liabilities | |||||
Long-term Debt | 168.9M | 132.2M | 162.9M | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 32.4K | 1.7M |
Other Non-Current Liabilities | 1 | - | - | -1.0K | 1.0K |
Total Non-Current Liabilities | 168.9M | 132.2M | 162.9M | 32.4K | 1.7M |
Total Liabilities | 614.5M | 535.2M | 458.0M | 242.1M | 191.9M |
Equity | |||||
Common Stock | 227.4M | 227.4M | 180.2M | 126.5M | 126.5M |
Retained Earnings | 562.6M | 399.5M | 297.5M | 236.6M | 195.5M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 1.9B | 1.8B | 865.2M | 438.2M | 397.1M |
Key Metrics | |||||
Total Debt | 271.1M | 189.4M | 173.4M | 101.2M | 73.6M |
Working Capital | 1.4B | 1.2B | 191.7M | 229.7M | 186.5M |
Balance Sheet Composition
Gennex Laboratories Cash Flow Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 214.0M | 164.9M | 63.7M | 52.8M | 50.6M |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | - | - | - | - | - |
Working Capital Changes | -229.8M | -668.8M | 57.7M | -3.0M | -26.0M |
Operating Cash Flow | -75.5M | -511.0M | 108.4M | 67.6M | 31.5M |
Investing Activities | |||||
Capital Expenditures | -87.5M | 153.5M | -397.4M | -15.7M | -787.8K |
Acquisitions | - | - | - | - | - |
Investment Purchases | - | 0 | -12.5M | 0 | - |
Investment Sales | - | - | - | - | - |
Investing Cash Flow | 8.2M | 151.2M | -409.9M | -15.7M | -787.8K |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | - | - | - | - | - |
Debt Issuance | - | 0 | 10.2M | 0 | 0 |
Debt Repayment | - | -30.7M | -90.7M | -37.0M | -154.9K |
Financing Cash Flow | 45.0M | 767.6M | 133.2M | -46.4M | 23.6M |
Free Cash Flow | -197.4M | -466.9M | -161.1M | 103.1M | -15.2M |
Net Change in Cash | -22.2M | 407.7M | -168.4M | 5.5M | 54.3M |
Cash Flow Trend
Gennex Laboratories Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
16.41
Price to Book
1.18
Price to Sales
2.16
PEG Ratio
2.80
Profitability Ratios
Profit Margin
11.46%
Operating Margin
13.37%
Return on Equity
9.31%
Return on Assets
7.08%
Financial Health
Current Ratio
4.07
Debt to Equity
13.93
Beta
0.31
Per Share Data
EPS (TTM)
₹0.78
Book Value per Share
₹10.85
Revenue per Share
₹7.07
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
gennex | 3.1B | 16.41 | 1.18 | 9.31% | 11.46% | 13.93 |
Sun Pharmaceutical | 4.0T | 37.73 | 5.42 | 15.08% | 19.29% | 3.26 |
Divi's Laboratories | 1.6T | 67.57 | 10.40 | 14.64% | 23.89% | 0.03 |
Innova Captab | 48.6B | 37.44 | 5.07 | 13.37% | 9.98% | 35.24 |
Suven Life Sciences | 48.0B | -28.31 | 41.36 | -146.15% | 84.44% | 0.00 |
Gujarat Themis | 46.2B | 103.15 | 18.55 | 19.64% | 30.17% | 12.27 |
Financial data is updated regularly. All figures are in the company's reporting currency.